I'm very interested in the effect on ROE, I suspect it will be a lower margin business than direct annuity writing.
All else being equal, the US$-denominated reinsurance business will be ROE-accretive, even though it will (self-evidently) entail a slight deterioration in the PCA Ratio.
Margins will almost certainly be lower vis-a-vis direct US$-denominated annuity writing, because MS&AD aren’t going to want to do it for nothing, i.e. they will most likely require from CGF a slightly higher fixed rate than the one they pay to their annuitants.
Given that the 20-year US Treasury yield is more than 50bp higher than the corresponding Australian yield, there is currently a bit more room to extract margin from US$-denominated annuities, though; therefore, CGF’s margins from US$-denominated reinsurance may not be significantly worse than the ones currently achievable from direct A$-denominated annuity writing.
My only concern is the reporting of this business unit & currency exposure. To me we now need to have 3 segments, Life, Funds Management & Re-insurance.
I don’t think so, because CGF are already doing A$-denominated reinsurance for MS&AD, without the need to report it under a separate segment. The net currency exposure is small, and easy to hedge.
Also curious how MS&AD apportion their risk, as part owners of their own re-insurance.
As 16%-owners of CGF (or whatever percentage they’re planning to increase their ownership to), MS&AD are going to retain 16% upside on the portion of risk that gets reinsured, plus a (small) fixed spread corresponding to the difference between the fixed rate they require from CGF and the one they offer to their customers.
Cheers
- Forums
- ASX - By Stock
- CGF
- News: CGF Challenger Ltd To Commence U.S. Dollar Annuity Reinsurance
News: CGF Challenger Ltd To Commence U.S. Dollar Annuity Reinsurance, page-4
-
-
- There are more pages in this discussion • 63 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add CGF (ASX) to my watchlist
(20min delay)
|
|||||
Last
$7.33 |
Change
0.450(6.54%) |
Mkt cap ! $5.065B |
Open | High | Low | Value | Volume |
$7.34 | $7.57 | $7.11 | $22.56M | 3.072M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 1367 | $7.31 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$7.35 | 3824 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 1367 | 7.310 |
1 | 6622 | 7.300 |
1 | 6622 | 7.280 |
1 | 6622 | 7.260 |
1 | 10000 | 7.250 |
Price($) | Vol. | No. |
---|---|---|
7.350 | 3824 | 2 |
7.370 | 4151 | 3 |
7.400 | 6622 | 1 |
7.420 | 8622 | 2 |
7.430 | 2000 | 1 |
Last trade - 16.10pm 13/08/2024 (20 minute delay) ? |
Featured News
CGF (ASX) Chart |
The Watchlist
ACW
ACTINOGEN MEDICAL LIMITED
Steven Gourlay, Managing Director and CEO
Steven Gourlay
Managing Director and CEO
SPONSORED BY The Market Online